NOVAVAX INC (NVAX)
US6700024010 - Common Stock
NVAX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. NVAX has a bad profitability rating. Also its financial health evaluation is rather negative. NVAX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NVAX has reported negative net income.
In the past year NVAX has reported a negative cash flow from operations.
In the past 5 years NVAX always reported negative net income.
In the past 5 years NVAX reported 4 times negative operating cash flow.
1.2 Ratios
NVAX's Return On Assets of -30.33% is fine compared to the rest of the industry. NVAX outperforms 73.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.33% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-42.37%
ROA(5y)-46.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVAX has a Gross Margin of 65.11%. This is amongst the best in the industry. NVAX outperforms 82.36% of its industry peers.
The Profit Margin and Operating Margin are not available for NVAX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVAX has more shares outstanding
The number of shares outstanding for NVAX has been increased compared to 5 years ago.
NVAX has a better debt/assets ratio than last year.
2.2 Solvency
NVAX has an Altman-Z score of -4.41. This is a bad value and indicates that NVAX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.41, NVAX is doing worse than 61.99% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.41 |
ROIC/WACCN/A
WACC6.97%
2.3 Liquidity
NVAX has a Current Ratio of 0.70. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.70, NVAX is doing worse than 93.84% of the companies in the same industry.
NVAX has a Quick Ratio of 0.70. This is a bad value and indicates that NVAX is not financially healthy enough and could expect problems in meeting its short term obligations.
NVAX's Quick ratio of 0.67 is on the low side compared to the rest of the industry. NVAX is outperformed by 93.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.7 | ||
| Quick Ratio | 0.67 |
3. Growth
3.1 Past
NVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.17%, which is quite impressive.
Looking at the last year, NVAX shows a very negative growth in Revenue. The Revenue has decreased by -50.36% in the last year.
The Revenue has been growing by 95.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)34.17%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q36.84%
Revenue 1Y (TTM)-50.36%
Revenue growth 3Y27.41%
Revenue growth 5Y95.67%
Revenue growth Q2Q-18.48%
3.2 Future
Based on estimates for the next years, NVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.15% on average per year.
Based on estimates for the next years, NVAX will show a small growth in Revenue. The Revenue will grow by 5.98% on average per year.
EPS Next Y85.31%
EPS Next 2Y42.22%
EPS Next 3Y29.15%
EPS Next 5Y15.15%
Revenue Next Year-16.27%
Revenue Next 2Y-4.31%
Revenue Next 3Y-2.88%
Revenue Next 5Y5.98%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVAX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
NVAX's earnings are expected to grow with 29.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.22%
EPS Next 3Y29.15%
5. Dividend
5.1 Amount
NVAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NOVAVAX INC
NASDAQ:NVAX (4/23/2024, 3:58:13 PM)
After market: 4.21 +0.02 (+0.48%)4.19
+0.12 (+2.95%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap586.39M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.33% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 65.11% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.7 | ||
| Quick Ratio | 0.67 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)34.17%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y85.31%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-50.36%
Revenue growth 3Y27.41%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y